STOCK TITAN
  1. Home
  2. News
  3. EQ

Equillium Inc - EQ STOCK NEWS

Welcome to our dedicated news page for Equillium (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Equillium's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Equillium's position in the market.

News
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Equillium, Inc. granted an inducement award of 10,000 nonstatutory stock options to a new employee under its 2024 Inducement Plan. The stock option has an exercise price of $2.11 per share, vesting over four years. This award aims to incentivize the new employee's continued service relationship with Equillium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
none
-
News
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Rhea-AI Summary
Equillium, Inc. (Nasdaq: EQ) announces positive topline data for itolizumab in lupus nephritis patients. More than 80% of subjects achieved a >50% reduction in urine protein creatinine ratio (UPCR). Itolizumab showed a favorable safety profile, triggering Ono Pharmaceutical's option exercise decision. The data suggests high response rates and rapid proteinuria reduction, comparable to voclosporin results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.66%
Tags
clinical trial
-
News
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Rhea-AI Summary
Equillium, Inc. (EQ) reported a $40.9 million cash balance at the end of 2023, providing cash runway into 2H 2025. They completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata, with topline data expected in Q2 2024. Positive data from Phase 1b EQUALISE study of itolizumab in lupus nephritis patients was presented at key medical meetings. Ono Pharmaceutical's option exercise decision for itolizumab is expected in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.57%
Tags
earnings
News
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
Rhea-AI Summary
Equillium, Inc. (EQ) to present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference and LD Micro Invitational Conference. Management to discuss clinical programs, partnership with Ono Pharmaceutical, and 2024 milestones. Webcasts available for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
conferences
-
News
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
Rhea-AI Summary
Equillium, Inc. (Nasdaq: EQ) has fully enrolled the EQ101 Phase 2 study in alopecia areata, with topline data expected in Q2 2024. EQ302, a new orally delivered multi-cytokine inhibitor, will be advanced instead of further clinical development of EQ102 due to its optimal delivery and increased potency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.59%
Tags
none
-
News
EQ Bank Card launches in Québec as Carte Banque EQ
Rhea-AI Summary
EQ Bank (Banque EQ in Québec) introduces the EQ Bank Card (Carte Banque EQ) to offer Québec customers a new way to earn, save, and spend money. The card allows free cash withdrawals from any ATM in Canada, cash-back rewards, high interest on card balance, and no foreign transaction fees. Customers can easily sign up for a Savings Plus Account and order a free card, combining a high-interest account with chequing account features. EQ Bank's deposit products are eligible for CDIC deposit insurance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
Rhea-AI Summary
Equillium, Inc. (Nasdaq: EQ) announced positive data from the Type B portion of the EQUALISE study, evaluating itolizumab in lupus nephritis patients. At Week 28, 73% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR). The results demonstrated a favorable safety and tolerability profile. The data presented highlights high complete and partial response rates, rapid and deep reduction in UPCR, and a greater overall response rate compared to standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
Rhea-AI Summary
Equillium, Inc. (Nasdaq: EQ) announced Q3 2023 financial results, highlighting $46.3 million in cash, clinical study updates, and upcoming milestones. The company's cash runway is expected to extend into 2025, with a focus on creating shareholder value. Revenue was $8.9 million, R&D expenses were $9.0 million, and net loss was $3.7 million for the quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
earnings
-
News
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
Rhea-AI Summary
Equillium, Inc. presented data from the EQUALISE study at the annual meeting of the American Society of Nephrology. The data showed high response rates and rapid reduction in urine protein creatinine ratio (UPCR) in lupus nephritis patients when itolizumab was added to the treatment. The study demonstrated both early and deep reductions in proteinuria, indicating potential long-term benefits for patients. The study also highlighted the favorable safety and tolerability profile of itolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors
Rhea-AI Summary
Persephone Biosciences appoints Daniel Bradbury as Chair of the Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Stock EQ logo
Equillium Inc

Nasdaq:EQ

EQ Rankings

#4631 Ranked by Market Cap
#5167 Ranked by Stock Gains
N/A Ranked by Dividends

EQ Stock Data

65.22M
17.76M
36.42%
21.65%
1.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
La Jolla

About EQ

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.